| 36.33 -0.3 (-0.82%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.91 | 1-year : | 50.12 |
| Resists | First : | 36.74 | Second : | 42.91 |
| Pivot price | 35.49  |
|||
| Supports | First : | 34.84 | Second : | 33.66 |
| MAs | MA(5) : | 36.2 |
MA(20) : | 35.29 |
| MA(100) : | 35.66 |
MA(250) : | 35.49 |
|
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 92.5 |
D(3) : | 93.9 |
| RSI | RSI(14): 59.4 |
|||
| 52-week | High : | 38.31 | Low : | 33.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GSK ] has closed below upper band by 19.7%. Bollinger Bands are 13% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.42 - 36.61 | 36.61 - 36.75 |
| Low: | 35.7 - 35.9 | 35.9 - 36.05 |
| Close: | 36.01 - 36.34 | 36.34 - 36.59 |
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Tue, 05 Dec 2023
GSK falls Tuesday, underperforms market - MarketWatch
Tue, 05 Dec 2023
JPMorgan Chase & Co. Raises Position in GSK plc (NYSE:GSK) - MarketBeat
Mon, 04 Dec 2023
Short Interest in GSK plc (NYSE:GSK) Declines By 6.5% - MarketBeat
Mon, 04 Dec 2023
GSK rises Monday, outperforms market - MarketWatch
Mon, 04 Dec 2023
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Sat, 02 Dec 2023
Boasting A 52% Return On Equity, Is GSK plc (LON:GSK) A Top Quality Stock? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—General
|
|
| Shares Out | 2,050 (M) |
| Shares Float | 3,930 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 13.6 (%) |
| Shares Short | 4,000 (K) |
| Shares Short P.Month | 4,840 (K) |
| EPS | 3.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.24 |
| Profit Margin | 20.4 % |
| Operating Margin | 31.3 % |
| Return on Assets (ttm) | 7.9 % |
| Return on Equity (ttm) | 61.2 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 9.71 |
| Sales Per Share | 14.46 |
| EBITDA (p.s.) | 4.48 |
| Qtrly Earnings Growth | -86.6 % |
| Operating Cash Flow | 5,480 (M) |
| Levered Free Cash Flow | 1,860 (M) |
| PE Ratio | 9.71 |
| PEG Ratio | 1.9 |
| Price to Book value | 11.2 |
| Price to Sales | 2.51 |
| Price to Cash Flow | 13.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|